This information is for Healthcare Professionals only.
Medical education activity sponsored by Bristol Myers Squibb Co.
Watch Part 2 of the Expert Webinar series on acute myeloid leukaemia (AML) maintenance therapy (catch up on Part 1 of the Expert Webinar series here). In this 1-hour webinar, Gail J Roboz and Klaus Metzeler delve into maintenance strategies, using clinical data and case studies to illustrate key considerations and best practices.
Topics covered include:
- The critical role of maintenance therapy for patients with AML.
- Overview of AML maintenance therapy evidence, including the latest data from the European Hematology Association (EHA) 2024 Congress.
- Patient cases representing current challenges and best practices for AML maintenance, including management of toxicities and considerations for specific subgroups, such as patients with FLT3-ITD-mutant AML or recurrence of measurable residual disease.
Presentations:
Welcome and Introductions (00:00:00–00:01:40)
Maintenance Therapy in AML – What’s the Evidence? (00:01:40–00:22:12; Gail J Roboz)
Maintaining Remission in AML – Clinical Case Studies (00:22:12–00:46:12; Klaus Metzeler)
Q&A and Closing Remarks (00:46:12–01:01:25)
Gail J Roboz
Weill Cornell Medicine, New York–Presbyterian Hospital, New York, USA
Klaus Metzeler
Klinik und Poliklinik fur Hämatologie, Universitätsklinikum Leipzig, Leipzig, Germany
Job bag code: HE-GL-2400095
Date of Prep: October 2024
